A groundbreaking Blood Pressure Treatment Efficacy Calculator, developed using data from nearly 500 randomized clinical trials involving more than 100,000 participants, now enables doctors to estimate how much different medications can lower a patient's blood pressure.

Recently published in The Lancet, the research behind this tool could transform how high blood pressure is managed. It allows doctors to tailor therapy to each patient's needs based on how much they need to reduce their blood pressure.

"This is really important because every 1mmHg reduction in systolic blood pressure lowers your risk of heart attack or stroke by two percent," said Nelson Wang, cardiologist and Research Fellow at The George Institute for Global Health.

"But with dozens of drugs, multiple doses per drug, and most patients needing two or more drugs, there are literally thousands of possible options, and no easy way to work out how effective they are," he said.

Turning Data Into Smarter Treatment Choices

The new calculator addresses this complexity by analyzing average treatment effects across hundreds of studies. It also classifies therapies as low, moderate, or high intensity, depending on how much they reduce blood pressure (BP) -- an approach already used in cholesterol management.

A single blood pressure medication, which is still the standard way most treatments begin, typically lowers systolic BP by only 8-9 mmHg. Many patients, however, need drops of 15-30 mmHg to reach healthy targets.

Dr. Wang explained that although doctors have traditionally adjusted therapy by monitoring each patient's blood pressure readings, those measurements are too variable to depend on alone.

The Problem With "Noisy" Blood Pressure Readings

"Blood pressure changes from moment to moment, day to day and by season -- these random fluctuations can easily be as big or larger than the changes brought about by treatment," he said.

"Also, measurement practices are often not perfect, bringing in an additional source of uncertainty -- this means it's very hard to reliably assess how well a medicine is working just by taking repeated measurements."

Anthony Rodgers, Senior Professorial Fellow at The George Institute for Global Health, noted that while high blood pressure is the most common reason people visit their doctor, there has never been a single, comprehensive source showing how effective different drugs are, particularly when combined or used at different doses.

A New Approach to Managing Hypertension

"Using the calculator challenges the traditional 'start low, go slow, measure and judge' approach to treatment, which comes with the high probability of being misled by BP readings, inertia setting in or the burden on patients being too much," he said.

"With this new method you specify how much you need to lower blood pressure, choose an ideal treatment plan to achieve that based on the evidence, and get the patient started on that ideally sooner rather than later."

The next step will be to test this approach in a clinical trial, where treatments are prescribed according to how much a patient needs to lower their blood pressure, using the calculator as a guide.

A Global Health Challenge

High blood pressure remains one of the world's most serious health threats, affecting an estimated 1.3 billion people and contributing to about ten million deaths every year.1

Often referred to as a "silent killer" because it produces no obvious symptoms, hypertension can go unnoticed until it leads to heart attack, stroke, or kidney disease. Fewer than one in five people with the condition have it adequately controlled.2

"Given the enormous scale of this challenge, even modest improvements will have a large public health impact -- increasing the percentage of people whose hypertension is under control globally to just 50% could save many millions of lives," Professor Rodgers said.

The Blood Pressure Treatment Efficacy Calculator is freely available at www.bpmodel.org[1].

Notes

  1. Global report on hypertension: the race against a silent killer. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO
  2. World Heart Federation. Hypertension. https://world-heart-federation.org/what-we-do/hypertension/[2]
Read more …New online tool can predict how well blood pressure drugs will work

This innovation, over 150 years in the making since the earliest bacterial cancer treatments, could open a new era of safe, immune-free cancer therapy.

Date:
Source:
Japan Advanced Institute of Science and Technology
Summary:
A Japanese-led research team has developed AUN, a groundbreaking immune-independent bacterial cancer therapy that uses two harmonized bacteria to destroy tumors even in patients with weakened immune systems. By leveraging the natural synergy between Proteus mirabilis and Rhodopseudomonas palustris, AUN selectively targets cancer cells, reshapes itself within tumors, and avoids harmful side effects like cytokine release syndrome.

FULL STORY


New Bacterial Therapy Destroys Cancer
The new AUN bacterial duo can eradicate tumors without the help of immune cells, offering hope for patients whose immune systems are compromised. Credit: Shutterstock

A research team led by Professor Eijiro Miyako at the Japan Advanced Institute of Science and Technology (JAIST), in collaboration with Daiichi Sankyo Co., Ltd. and the University of Tsukuba, has created an innovative cancer treatment that works without relying on the immune system. The new approach uses a unique microbial partnership known as AUN, forming the foundation of an immune-independent bacterial therapy.

The concept of bacterial cancer therapy dates back to 1868, when German physician Busch reported that a cancer patient deliberately infected with bacteria later experienced remission. In 1893, Dr. William Coley further advanced this idea by developing bacterial-based treatments, paving the way for modern immunotherapies such as checkpoint inhibitors and CAR-T cell therapies.

While these treatments have transformed cancer care, they share a major drawback: they depend heavily on the immune system. For patients whose immunity is weakened by chemotherapy or radiotherapy, such therapies often fail to work effectively.

AUN: Two Bacteria in Perfect Balance

The newly developed AUN therapy directly overcomes this limitation. It is made up of two naturally occurring bacterial species:

  • Proteus mirabilis (A-gyo), a bacterium that naturally resides in tumors
  • Rhodopseudomonas palustris (UN-gyo), a photosynthetic bacterium

Together, these bacteria act in harmony to destroy cancer cells in both animal and human models. Remarkably, they succeed even when immune function is impaired. AUN has shown strong compatibility with the human body and few side effects, including suppression of cytokine release syndrome (CRS), a potentially dangerous immune reaction.

How AUN Works to Eliminate Tumors

The AUN consortium achieves its tumor-fighting power through a series of coordinated mechanisms:

  • Precisely targeting and destroying tumor blood vessels and cancer cells
  • Undergoing a structural transformation in A-gyo (filamentation) triggered by tumor-specific metabolites, which enhances its ability to kill cancer cells
  • Adjusting the bacterial ratio inside the tumor environment, shifting from an initial mix of roughly 3:97 (A-gyo to UN-gyo) to about 99:1, maximizing its therapeutic strength
  • Reducing toxicity and minimizing side effects, including avoidance of CRS

Harmony Between Opposites

UN-gyo only becomes active and beneficial when paired with A-gyo, serving as a regulator that curbs harmful bacterial activity while increasing their cancer-killing precision. This mutual cooperation embodies the Japanese concept of "AUN," symbolizing balance and harmony between opposites. It is this finely tuned relationship that gives the therapy its exceptional results, achieving what traditional immune-dependent treatments could not.

Toward Clinical Trials and a New Era in Cancer Therapy

"We are preparing to launch a startup to advance this technology and hope to begin clinical trials within six years," explained Professor Miyako. "A new chapter in bacteria-based cancer therapy -- pursued for over 150 years -- is finally beginning."

This groundbreaking method marks a turning point for cancer patients with weakened immune systems. It offers a long-sought option where conventional immunotherapies fall short, signaling the arrival of truly immune-independent cancer treatment.

The findings have been published in Nature Biomedical Engineering.


Story Source:

Materials provided by Japan Advanced Institute of Science and Technology. Note: Content may be edited for style and length.


Journal Reference:

  1. Seigo Iwata, Taisei Nishiyama, Matomo Sakari, Yuki Doi, Naoki Takaya, Yusuke Ogitani, Hiroshi Nagano, Keisuke Fukuchi, Eijiro Miyako. Tumour-resident oncolytic bacteria trigger potent anticancer effects through selective intratumoural thrombosis and necrosis. Nature Biomedical Engineering, 2025; DOI: 10.1038/s41551-025-01459-9[1]

Cite This Page:

Japan Advanced Institute of Science and Technology. "New bacterial therapy destroys cancer without the immune system." ScienceDaily. ScienceDaily, 9 November 2025. <www.sciencedaily.com/releases/2025/11/251109013250.htm>.

Japan Advanced Institute of Science and Technology. (2025, November 9). New bacterial therapy destroys cancer without the immune system. ScienceDaily. Retrieved November 9, 2025 from www.sciencedaily.com/releases/2025/11/251109013250.htm

Japan Advanced Institute of Science and Technology. "New bacterial therapy destroys cancer without the immune system." ScienceDaily. www.sciencedaily.com/releases/2025/11/251109013250.htm (accessed November 9, 2025).

RELATED STORIES


Trojan Horse Bacteria Sneak Cancer-Killing Viruses Into Tumors[2]

Aug. 17, 2025 — Scientists have engineered a groundbreaking cancer treatment that uses bacteria to smuggle viruses directly into tumors, bypassing the immune system and delivering a powerful one-two punch against ...

Maintaining Balance in the Immune System[3]

May 19, 2025 — Researchers have published the first description of the role of the ZFP36 family of RNA binding proteins in regulatory T cells (Tregs). Tregs are key to maintaining balance in the immune system and ...

How Cancer Cells Trick the Immune System by Altering Mitochondria[4]

Feb. 11, 2025 — Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment. However, cancer cells have developed immune evasion strategies, leading to ...

A New Targeted Treatment Calms the Cytokine Storm[5]

Jan. 17, 2024 — Researchers have discovered a novel treatment to relieve cytokine release syndrome (CRS), a life-threatening inflammation triggered by a serious infection or severe burn. Treatment with a ...

Switching Off the Cytokine Storm[6]

Sep. 14, 2023 — Researchers provide essential insights on the molecular activation of the MAP kinase p38?, the final switch triggering the inflammatory response. Inflammation is a cellular coping mechanism when ...

Japanese Beetles Could Spread Throughout Washington State, US, in 20 Years[7]

July 18, 2023 — Without intervention, the colorful but devastating Japanese beetle could make its way across the evergreen state within two decades, according to a study of their potential dispersion. The ...

TRENDING AT SCITECHDAILY.com[8]


Poor Oral Health Linked to Hidden Brain Damage[9]

GLP-1 Drugs Like Ozempic Work, but New Research Reveals a Major Catch[10]

New Research Shatters the Myth of Gluten Sensitivity[11]

Researchers Shatter “Impassable Barrier” in Camera Technology[12]

Read more …New bacterial therapy destroys cancer without the immune system

More Articles …